Dallo Ignacio, Szwedowski Dawid, Mobasheri Ali, Irlandini Eleonora, Gobbi Alberto
O.A.S.I. Bioresearch Foundation, Gobbi NPO, Milano, Italy.
Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland.
Stem Cells Dev. 2021 Jul 1;30(13):651-659. doi: 10.1089/scd.2021.0053. Epub 2021 May 24.
The objective of this study was to compare the clinical efficacy of repeated doses of leucocyte-poor platelet-rich plasma (LP-PRP) plus hyaluronic acid (HA) to a single dose of autologous microfragmented adipose tissue (AMAT) injections in patients with early osteoarthritis (OA) symptoms. Eighty knees in 50 patients (mean age: 61.3 years) were randomly allocated into two equal groups in a nonblinded design and prospectively followed for 12 months. Group 1 received three intra-articular injections (1 month apart) using autologous LP-PRP+HA. Group 2 received a single dose of AMAT injection. Outcomes were measured by PROMs Tegner, Marx, visual analog scale, and Knee Injury and Osteoarthritis Outcome Score (KOOS) at 6 and 12 months. Both groups had significant clinical and functional improvement at 6 and 12 months. The differences between groups were statistically significant in Tegner score and KOOS symptoms (both < 0.05) at 6 months in group 2. The test with statistically significant differences ( < 0.05) at 12 months was Tegner ( < 0.001), with group 2 having a higher median than group 1. LP-PRP+HA and AMAT lead to clinical and functional improvement at 6 and 12 months. AMAT showed better clinical results in Tegner and KOOS symptoms at 6 months and Tegner at 12 months. Understanding which therapy offers the most benefits with the least risk can significantly improve the quality of life for millions of people affected by OA. Long-term randomized controlled studies are needed to verify differences in efficacy.
本研究的目的是比较重复剂量的低白细胞富血小板血浆(LP-PRP)加透明质酸(HA)与单剂量自体微片段化脂肪组织(AMAT)注射对早期骨关节炎(OA)症状患者的临床疗效。50例患者(平均年龄:61.3岁)的80个膝关节采用非盲法设计随机分为两组,前瞻性随访12个月。第1组接受3次关节内注射(间隔1个月),使用自体LP-PRP+HA。第2组接受单剂量AMAT注射。在6个月和12个月时,通过PROMs Tegner、Marx、视觉模拟量表和膝关节损伤与骨关节炎转归评分(KOOS)来衡量结果。两组在6个月和12个月时均有显著的临床和功能改善。在6个月时,第2组的Tegner评分和KOOS症状方面两组间差异有统计学意义(均P<0.05)。在12个月时有统计学显著差异(P<0.05)的检验是Tegner(P<0.001),第2组的中位数高于第1组。LP-PRP+HA和AMAT在6个月和12个月时均导致临床和功能改善。AMAT在6个月时的Tegner和KOOS症状以及12个月时的Tegner方面显示出更好的临床结果。了解哪种治疗在风险最小的情况下提供最大益处可以显著改善数百万受OA影响人群的生活质量。需要长期随机对照研究来验证疗效差异。